New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
07:06 EDTTBIOTransgenomic enters agreement with DNA Technologies
Transgenomic announced that it has entered into an agreement to sell to Integrated DNA Technologies the rights to Transgenomic’s SURVEYOR Nuclease technology and assets for a minimum of $4.25M. Under the terms of the agreement, IDT will make an upfront payment of $3.65M and additional minimum payments of $0.6M or more to Transgenomic during the first year of the agreement. Transgenomic will transfer rights to the SURVEYOR patents, license, technology, know-how and trademarks to IDT, as well as all inventory of the product. As part of the agreement, IDT will exclusively sublicense rights for all clinical and diagnostic applications of the SURVEYOR technology back to Transgenomic. Further terms of the agreement were not disclosed.
News For TBIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
07:41 EDTTBIOTransgenomic launches ICEme Mutation Enrichment Kits
Subscribe for More Information
June 22, 2015
07:06 EDTTBIOTransgenomic plans to launch six new genetic cancer tests this year
Transgenomic announced that it is planning to launch up to six new genetic cancer tests this year based on its Multiplexed ICE COLD-PCR, or MX-ICP, technology. The new tests will focus on actionable genetic mutations and alterations in patients with melanoma, non-small cell lung cancer, or NSCLC, and colorectal cancer, and will include both single tests and multi-gene panels. Transgenomic’s MX-ICP technology has demonstrated exceptional sensitivity and accuracy using either standard tissue or liquid biopsy samples such as blood and plasma. The tests are expected to be available for diagnostic use through Transgenomic’s CLIA-certified laboratory. “We are ahead of schedule in commercializing our pipeline of laboratory-based cancer tests to meet the growing demand for targeted and personalized cancer treatments,” said Paul Kinnon, president and CEO of Transgenomic. “The unsurpassed accuracy of our Multiplexed ICE COLD-PCR technology and its ability to produce highly sensitive and accurate results from small amounts of virtually any type of patient sample enable its broad use for tumor detection and monitoring. The fact that MX-ICP is a platform technology is also facilitating the rapid development of our pipeline. We intend to release two or three new single and panel tests per quarter for the remainder of this year, focusing on the two most prevalent cancers--colorectal and lung, as well as melanoma, which is especially amenable to targeted therapies.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use